首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1462632篇
  免费   101906篇
  国内免费   2382篇
耳鼻咽喉   21054篇
儿科学   44483篇
妇产科学   39132篇
基础医学   227555篇
口腔科学   40825篇
临床医学   130017篇
内科学   270711篇
皮肤病学   31530篇
神经病学   112438篇
特种医学   57992篇
外国民族医学   221篇
外科学   224955篇
综合类   31851篇
现状与发展   4篇
一般理论   398篇
预防医学   109270篇
眼科学   34033篇
药学   111023篇
  1篇
中国医学   2847篇
肿瘤学   76580篇
  2018年   15172篇
  2017年   11776篇
  2016年   13854篇
  2015年   14999篇
  2014年   20241篇
  2013年   31293篇
  2012年   43141篇
  2011年   46842篇
  2010年   27007篇
  2009年   23729篇
  2008年   44122篇
  2007年   48113篇
  2006年   47162篇
  2005年   46181篇
  2004年   44966篇
  2003年   43620篇
  2002年   42139篇
  2001年   59772篇
  2000年   62050篇
  1999年   50682篇
  1998年   15153篇
  1997年   13429篇
  1996年   13214篇
  1995年   12347篇
  1994年   11648篇
  1992年   40154篇
  1991年   41022篇
  1990年   40623篇
  1989年   39493篇
  1988年   36650篇
  1987年   36389篇
  1986年   34214篇
  1985年   33305篇
  1984年   25530篇
  1983年   21754篇
  1982年   13161篇
  1981年   12126篇
  1979年   25301篇
  1978年   18331篇
  1977年   15253篇
  1976年   14761篇
  1975年   16602篇
  1974年   19839篇
  1973年   19040篇
  1972年   17917篇
  1971年   16800篇
  1970年   15925篇
  1969年   15182篇
  1968年   13940篇
  1967年   12718篇
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
21.
22.
23.
24.
Pharmaceutical Chemistry Journal - An HPLC-MS method for simultaneous quantitative determination of a novel gestagenic pharmaceutical and two of its metabolites in rat and rabbit blood sera was...  相似文献   
25.
26.
Bulletin of Experimental Biology and Medicine - Ammonium, an end-product of catabolism, in low doses can promote adaptation of metabolic pathways in erythrocytes under conditions of extreme...  相似文献   
27.
28.
Objective: Human epidermal growth factor receptor 2 (erbb2/HER2) overexpression, has now been implicatedin advanced gastric and gastroesophageal junction cancers. The study was conducted to determine the rate of HER2positivity in patients with locally advanced or metastatic gastric and gastroesophageal adenocarcinoma in North-EastIndia and to assess the impact of various demographic and clinical parameters on HER2 positivity. Methods: A total of68 patients of age >18 years of gastric and gastroesophageal adenocarcinoma diagnosed on histopathological examinationfrom September 2016 to February 2018 at Dr B Borooah Cancer Institute, Assam were enrolled for the observational(epidemiological) study. All patients were subjected to the HER2 immunohistochemistry test using a FDA-approved,standardized test kit. HER2 expression was correlated with various demographic and clinicopathological parameters.Results: The overall rate of HER2 positivity in the population studied was 56% (n=38). The rate was non-significantlyhigher in male, older age group (>60 years) and Hindu population. Similarly, HER2 positivity rate was higher in patientswith well differentiated histology and was more common in patients with stage II and III diseases, but neither of theassociations is statistically significant. HER2 positivity rate was significantly higher in proximal and in GEJ tumours(56% versus 44%, P=0.002). Conclusion: HER2 overexpression was evident in 56% of the North-East Indian patientswith locally advanced and metastatic gastric and gastroesophageal adenocarcinoma. The overexpression correlatedsignificantly with primary tumour site. Routine testing of gastric and gastroesophageal tumours for HER2 expressionis recommended to provide a therapeutic advantage in Indian patients.  相似文献   
29.
30.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号